SMC’s Pharmacy Acclaimed for Global Top Performance of Chemotherapy Drug Compounding Robot Utilization
.jpg)
An Italian robot manufacturer, LOCCIONI, promoted how well SMC’s pharmacy is using its chemotherapy drug compounding robot, APOTECAchemo, to global medical institutions through its community newsletter and website.
Just three weeks after introducing the robot, the pharmacy achieved 1.5 times more chemotherapy compounding than other medical institutions using automated compounding robots. The compounding success rate was as perfect as 100% without any technical issue, even though it hasn’t been operated very long. With this record-breaking performance achieved in the shortest amount of time, the pharmacy outperformed other 36 top global medical institutions in 12 countries that use the robot.
LOCCIONI promoted this case to the community of the world’s top hospitals including Johns Hopkins Hospital and Cleveland Clinic which also run chemotherapy compounding robots by describing how the pharmacy at SMC analyzed work thoroughly, conducted trainings in advance, and optimized the operating environment to deliver excellent performance.
For the first time in Korea, the pharmacy adopted one APOTECAchemo robot that automatically compounds high-risk ready-to-inject chemotherapy drugs after three years of consideration, as part of its ongoing effort to reinforce patient safety control and ensure pharmacists’ healthy.
